Guardant Health CMO to Resign; Delfi and Singular Name New Leaders
Guardant Health said its chief medical officer will resign effective May 8, while Delfi Diagnostics appointed Charles Newton to its board and Singular Genomics named John Stark CEO.
Guardant Health
CompanyAlso known as: Guardant Health
Company Profile
Guardant Health is a precision oncology company focused on blood-based cancer testing and data-driven cancer care. Founded in 2012 and headquartered in Redwood City, it is listed on Nasdaq under GH.
- Website
- https://guardanthealth.com
- Headquarters
- Redwood City, California, USA
- Founded
- 2012
- Stock Ticker
- NASDAQ:GH
Related News
AI-Driven Precision Medicine Market to Reach $9.7 Billion by 2035
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
Oncology Precision Medicine Market to Reach $366.53 Billion by 2033
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.